CoChat

Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial

Open access
Glynn, Robert J., Koenig, Wolfgang, Nordestgaard, Børge G., Shepherd, James, Ridker, Paul M · 2010 · Annals of Internal Medicine

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Randomized data on statins for primary prevention in older persons are limited, and the relative hazard of cardiovascular disease associated with an elevated cholesterol level weakens with advancing age. OBJECTIVE: To assess the efficacy and safety of rosuvastatin in persons 70 years or older. DESIGN: Secondary analysis of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), a randomized, double-blind, placebo-controlled trial. SETTING: 1315 sites in 26 countries randomly assigned participants in JUPITER. PARTICIPANTS: Among the 17 802 participants randomly assigned with low-density lipoprotein (LDL) cholesterol levels less than 3.37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein levels of 2.0 mg/L or more without cardiovascular disease, 5695 were 70 years or older. INTERVENTION: Participants were randomly assigned in a 1:1 ratio to receive 20 mg of rosuvastatin daily or placebo. MEASUREMENTS: The primary end point was the occurrence of a first cardiovascular event (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes). RESULTS: The 32% of trial participants 70 years or older accrued 49% (n = 194) of the 393 confirmed primary end points. The rates of the primary end point in this age group were 1.22 and 1.99 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio, 0.61 [95% CI, 0.46 to 0.82]; P < 0.001). Corresponding rates of all-cause mortality in this age group were 1.63 and 2.04 (hazard ratio, 0.80 [CI, 0.62 to 1.04]; P = 0.090). Although no significant heterogeneity was found in treatment effects by age, absolute reductions in event rates associated with rosuvastatin were greater in older persons. The relative rate of any serious adverse event among older persons in the rosuvastatin versus placebo group was 1.05 (CI, 0.93 to 1.17). LIMITATION: Effect estimates from this exploratory analysis with age cut-point chosen after trial completion should be viewed in the context of the overall trial results. CONCLUSION: In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events. PRIMARY FUNDING SOURCE: AstraZeneca.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-152-8-201004200-00005

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 256

Metadata

Authors
Glynn, R. J., Koenig, W., Nordestgaard, B. G., Shepherd, J., & Ridker, P. M.
Affiliations
  • University of Copenhagen (DK)
  • From Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Ulm, Ulm, Germany; Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Herlev, Denmark; and the University of Glasgow, Glasgow, United Kingdom.
Venue
Annals of Internal Medicine
Published
2010-04-20
Volume
152
Issue
8
Pages
488-496
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W169219636
Cited by
252
References
29
Citations by year
2026: 6 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 13 · 2021: 17 · 2020: 13 · 2019: 23 · 2018: 14 · 2017: 15 · 2016: 15 · 2015: 19 · 2014: 17 · 2013: 19 · 2012: 18
FWCI
26.02
Type
journal article
Language
en
Open access
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Annals of Internal Medicine
Funders
National Institute on Aging (R01-AG18833, R56AG018833, R01AG018833)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
rosuvastatin, statins, primary prevention, older adults, high-sensitivity C-reactive protein, low LDL cholesterol, cardiovascular events, all-cause mortality, serious adverse events, JUPITER trial, cardiovascular risk stratification, drug safety in elderly
MeSH terms
Rosuvastatin Calcium, Aged, Aged, 80 and over, C-Reactive Protein, Cardiovascular Diseases, Cause of Death, Double-Blind Method, Female, Fluorobenzenes, Humans, Cholesterol, LDL, Male, Primary Prevention, Pyrimidines, Sulfonamides, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-152-8-201004200-00005
The paper
Glynn, R. J., Koenig, W., Nordestgaard, B. G., Shepherd, J., & Ridker, P. M. (2010). Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-152-8-201004200-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.